IDEAYA Biosciences Enrolls First Patient in Phase 1 Clinical Trial for Innovative Cancer Treatment IDE574 IDEAYA Biosciences has commenced its Phase 1 trial for IDE574, a promising dual inhibitor targeting KAT6 and KAT7 in various solid tumors, showing hope for patients with challenging cancers.

IDEAYA Biosciences Enrolls First Patient in Phase 1 Clinical Trial for Innovative Cancer Treatment IDE574 #United_States #IDEAYA_Biosciences #South_San_Francisco #KAT6/7 #IDE574

IDEAYA Biosciences Advances Cancer Treatment with IND Submission for IDE574 Dual Inhibitor IDEAYA Biosciences has submitted an IND application for IDE574, a potential first-in-class dual inhibitor targeting breast and lung cancers, starting trials in early 2026.

IDEAYA Biosciences Advances Cancer Treatment with IND Submission for IDE574 Dual Inhibitor #USA #Cancer_Treatment #IDEAYA_Biosciences #South_San_Francisco #IDE574